Komori

Supplementary Financial Results Materials for the Third Quarter of the Fiscal Year Ending December 2026

Supplementary dataNine months, FY ending Dec 2026Published 2026-11-10 16:00

In the third quarter of the fiscal year ending December 2026, revenue increased and operating loss, ordinary loss and net loss all narrowed from the same period of the previous fiscal year, driven by higher revenue from the drug discovery support business and lower research and development expenses and other costs. On the business front, progress was made on clinical trials for CBA-1205 and collaborative research using DoppeLib®.

In short

  • Revenue for the cumulative third quarter was ¥406 million, up 10.0% year on year.
  • Operating loss was ¥736 million, narrowing by ¥68 million from the same period of the previous fiscal year.
  • Patient enrollment was completed for CBA-1205 in patients with hepatocellular carcinoma and melanoma, and a collaborative research agreement was signed with FRONTEO for DoppeLib®.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥406.0m+10.0%vs a year earlier
9M FY25/12¥369.0m9M FY26/12¥406.0m
FY24/12FY25/12FY26/12 · this year0200400¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+7%+12%+13%this yearvs same quarter last yearlast year
Sales by quarter
Period¥m
FY24/12 Q1129.0
FY24/12 Q2134.0
FY24/12 Q3159.0
FY24/12 Q4358.0
FY25/12 Q1138.0
FY25/12 Q2113.0
FY25/12 Q3118.0
FY25/12 Q4224.0
FY26/12 Q1147.0
FY26/12 Q2126.0
FY26/12 Q3133.0
Why

Revenue related to biosimilars increased in the drug discovery support business.

製薬企業向けの研究支援の売上高が減少・バイオシミラー関連の売上高が拡大
Revenue from research support for pharmaceutical companies declined, while revenue related to biosimilars increased
Bright spot

Revenue from the drug discovery support business increased 10.0% year on year.

2026年12月期3Qの売上高は406百万円。前年同期比10.0%の増収。
Revenue for the third quarter of the fiscal year ending December 2026 was ¥406 million. Revenue increased 10.0% year on year.

Operating profit

−¥736.0mloss narrowedvs a year earlier
9M FY25/12−¥805.0m9M FY26/12−¥736.0m
FY24/12FY25/12FY26/12 · this year-300-200-100¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4smaller lossthis yearvs same quarter last yearlast year
Operating profit by quarter
Period¥m
FY24/12 Q1-322.0
FY24/12 Q2-259.0
FY24/12 Q3-339.0
FY24/12 Q4-110.0
FY25/12 Q1-264.0
FY25/12 Q2-272.0
FY25/12 Q3-269.0
FY25/12 Q4-174.0
FY26/12 Q1-232.0
FY26/12 Q2-247.0
FY26/12 Q3-257.0
Why

Research and development expenses and other costs declined.

臨床開発関連費用等の減少
Lower clinical development-related costs and other expenses

Ordinary profit

−¥737.0mloss narrowedvs a year earlier
9M FY25/12−¥807.0m9M FY26/12−¥737.0m
FY24/12FY25/12FY26/12 · this year-300-200-100¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4smaller lossthis yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥m
FY24/12 Q1-303.0
FY24/12 Q2-260.0
FY24/12 Q3-351.0
FY24/12 Q4-105.0
FY25/12 Q1-265.0
FY25/12 Q2-274.0
FY25/12 Q3-268.0
FY25/12 Q4-182.0
FY26/12 Q1-232.0
FY26/12 Q2-249.0
FY26/12 Q3-256.0

Net profit

−¥739.0mloss narrowedvs a year earlier
9M FY25/12−¥800.0m9M FY26/12−¥739.0m
FY24/12FY25/12FY26/12 · this year-300-200-100¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4smaller lossthis yearvs same quarter last yearlast year
Net profit by quarter
Period¥m
FY24/12 Q1-304.0
FY24/12 Q2-259.0
FY24/12 Q3-352.0
FY24/12 Q4-105.0
FY25/12 Q1-266.0
FY25/12 Q2-274.0
FY25/12 Q3-260.0
FY25/12 Q4-182.0
FY26/12 Q1-233.0
FY26/12 Q2-250.0
FY26/12 Q3-256.0

Their own numbers

figures this company chose to report, a year ago against now
Number of employees
63 people

As of 30 September 2026, the company had 63 employees.

Dose administered in the first part of the Phase 1 clinical trial of CBA-1205
30 mg/kg

Doses of up to 30 mg/kg were administered in the first part, confirming a high level of safety.

Number of patients evaluated in the Phase 1 clinical trial of CBA-1205
22 people

A total of 22 people are included in the table of adverse events related to CBA-1205.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

By business

bar = share of sales · rows = operating profit and change vs a year earlier
Drug Discovery Support Business 100%
sales ¥406.0m +10.0%
profit not stated

New initiatives

what they said they're starting
  • In September 2026, a collaborative research agreement was signed with FRONTEO to develop bispecific antibody therapeutics using DoppeLib®.
  • Alfresa HD, キッズウェル, Mycenax and the company are jointly advancing the development of domestic manufacturing facilities for biopharmaceuticals.
  • Patient enrollment and dosing are underway in the pediatric cancer arm of CBA-1205.
  • The monotherapy arm of CBA-1535 has been extended to expand the clinical data ahead of out-licensing.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-218.2%now-181.3%

Overheads (selling and admin costs): ¥1.1bn

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-64.6%
profit earned on shareholders' money
+1.7 pts on last year
-85%-71%-57%FY21/12FY22/12FY23/12FY24/12FY25/12FY21/12: -59.1%FY22/12: -67.4%FY23/12: -82.8%FY24/12: -66.3%FY25/12: -64.6%-64.6%
Return on equity
Period%
FY21/12-59.1
FY22/12-67.4
FY23/12-82.8
FY24/12-66.3
FY25/12-64.6
Equity ratio82.0%
how much of the balance sheet is owned outright
+17.9 pts on last year
62%73%84%FY21/12FY22/12FY23/12FY24/12FY25/12FY26/12FY21/12: 79.4%FY22/12: 80.2%FY23/12: 65.1%FY24/12: 77.4%FY25/12: 64.1%FY26/12: 82.0%82.0%
Equity ratio
Period%
FY21/1279.4
FY22/1280.2
FY23/1265.1
FY24/1277.4
FY25/1264.1
FY26/1282.0

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Headcount

people against what they produce
63peopleas of 2026/09

Not mentioned in this deck

14
What movedCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countMarket size and shareInvestor Q&A
Supplementary Financial Results Materials for the Third Quarter of the Fiscal Year Ending December 2026 | Chiome Bioscience Inc. (4583) timely disclosure | Komori